Dyslipidemia and Hematological Abnormalities in Hemodialysis Patients: A Study on the Progression of Chronic Kidney Disease in Karbala Governorate
Keywords:
Dyslipidemia, Hemodialysis, Chronic Kidney Disease, Hematological Parameters, Lipid ProfileAbstract
Chronic Kidney Disease (CKD) is a significant global health concern impacting various physiological systems. This study investigates the effects of CKD on lipid profiles and complete blood count (CBC) in hemodialysis patients. The aim was to evaluate the alterations in these parameters in CKD patients undergoing dialysis and to understand their correlation with disease severity. A case-control study was conducted at Imam Hussein Teaching Hospital in Karbala Governorate, Iraq. The study included 80 patients (51 males and 29 females) aged between 21 and 62 years, who suffered from CKD and were undergoing renal dialysis for periods ranging from three months to 15 years. Patients were divided into two groups: those undergoing dialysis for more than a year (40 samples) and those undergoing dialysis for less than a year (40 samples). Blood samples were collected and analyzed for RBC, WBC, Hb, PLT, Cholesterol, HDL, and Triglyceride levels. The findings indicated a clear inverse relationship between CKD severity and mean levels of RBC, Hb, and PLT, with these levels decreasing significantly as the disease severity increased. While total cholesterol, triglyceride levels, and white blood cell count were relatively elevated with increasing disease severity, high-density lipoprotein (HDL) cholesterol levels remained stable in this study and were not affected by disease severity. The results of this study indicate that chronic kidney disease affects blood parameters, lipid metabolism, and lipid dysregulation. Therefore, it is essential to monitor lipid levels and blood parameters periodically in dialysis patients due to the increased risk of cardiovascular disease and other associated systemic risks.
Downloads
References
[1] Adams GR, Vaziri ND. Skeletal muscle dysfunction in chronic renal failure: effects of exercise. American Journal of Physiology-Renal Physiology 2006.
[2] Zuzda K, Walczak-Wieteska P, Andruszkiewicz P, Małyszko J. Acute Kidney Injury Biomarkers in Perioperative Care: A Scoping Review of Clinical Implementation. Diagnostics 2025; 16:94.
[3] Webster AC, Nagler E V, Morton RL, Masson P. Chronic kidney disease. The Lancet 2017; 389:1238–52.
[4] Makris K. The role of the clinical laboratory in the detection and monitoring of acute kidney injury. J Lab Precis Med 2018;3.
[5] Khudhair DA, Kareem HL, Yaseen MA, Mohammed HA. Assessment of Arginase II with Biochemical Changes in Patients with Chronic Kidney Disease. Medical Journal of Babylon 2024; 21:748–52.
[6] Raoof AA, Al-Saedi AJH, Nabil D. Correlation of Fibroblast Growth Factor-23 with Thyroid Disorder in Patients with Chronic Kidney Disease. Medical Journal of Babylon 2025; 22:28–32.
[7] Habib A, Ahmad R, Rehman S. Hematological changes in patients of chronic renal failure and the effect of hemodialysis on these parameters. Int J Res Med Sci 2017; 5:4998–5003.
[8] Nissenson AR, Fine RN, Mehrotra R, Zaritsky J. Handbook of dialysis therapy, E-Book. Elsevier Health Sciences; 2022.
[9] Himmelfarb J, Vanholder R, Mehrotra R, Tonelli M. The current and future landscape of dialysis. Nat Rev Nephrol 2020; 16:573–85.
[10] Ghodsian S, Ghafourifard M, Ghahramanian A. Comparison of shared decision making in patients undergoing hemodialysis and peritoneal dialysis for choosing a dialysis modality. BMC Nephrol 2021; 22:67.
[11] Lacquaniti A, Bolignano D, Donato V, Bono C, Fazio MR, Buemi M. Alterations of lipid metabolism in chronic nephropathies: mechanisms, diagnosis and treatment. Kidney Blood Press Res 2010; 33:100–10.
[12] Hall YN, Larive B, Painter P, Kaysen GA, Lindsay RM, Nissenson AR, et al. Effects of six versus three times per week hemodialysis on physical performance, health, and functioning: Frequent Hemodialysis Network (FHN) randomized trials. Clinical Journal of the American Society of Nephrology 2012; 7:782–94.
[13] Lacount S, Tannock LR. Dyslipidemia in Chronic Kidney Disease. In: Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; Updated 2025 Apr 30.
[14] Moradi H, Vaziri ND, Kashyap ML, Said HM, Kalantar-Zadeh K. Role of HDL dysfunction in end-stage renal disease: a double-edged sword. Journal of Renal Nutrition 2013; 23:203–6.
[15] Barbagallo CM, Cefalù AB, Giammanco A, Noto D, Caldarella R, Ciaccio M, et al. Lipoprotein abnormalities in chronic kidney disease and renal transplantation 2021;11:315.
[16] Gao F, Feng G, Li H, Qin W, Xiao C. Scavenger receptor BI induced by HDL from coronary heart disease may be related to atherosclerosis. Clinical and Applied Thrombosis/Hemostasis 2021; 27:10760296211029710.
[17] Lee W-C, Chen J-B, Moi S-H, Yang C-H. Association of proportion of the HDL-cholesterol subclasses HDL-2b and HDL-3 and macrovascular events among patients undergoing hemodialysis. Sci Rep 2021; 11:1871.
[18] Tsinari A, Roumeliotis S, et al. The Clinical Utility and Plausibility of Oxidative and Antioxidant Variables in Chronic and End-Stage Kidney Disease: A Review of the Literature. Int J Mol Sci. 2025;26(7):3376.
[19] Honda H, Ueda M, Kojima S, Mashiba S, Michihata T, Takahashi K, et al. Oxidized high-density lipoprotein as a risk factor for cardiovascular events in prevalent hemodialysis patients. Atherosclerosis 2012; 220:493–501.
[20] Deebel NA, Matthew AN, Loloi J, Bernstein AP, Thirumavalavan N, Ramasamy R. Testosterone deficiency in men with end stage renal disease and kidney transplantation: a narrative review. Int J Impot Res 2025; 37:271–7.
[21] Kazmi S, Zarovniaeva V, Cortez Perez K, et al. Iron-Deficiency Anemia in Chronic Kidney Disease: A Literature Review of Its Pathophysiology, Diagnosis, and Management. Cureus. 2025
[22] Kenkre JS, Mazaheri T, Neely RDG, Soran H, Datta D, Penson P, et al. Standardising lipid testing and reporting in the United Kingdom; a joint statement by HEART UK and The Association for Laboratory Medicine. Ann Clin Biochem 2025; 62:257–86.
[23] Sevinc C, Yilmaz G, Ustundag S. The relationship between calcification inhibitor levels in chronic kidney disease and the development of atherosclerosis. Ren Fail 2021; 43:1349–58.
[24] Gwozdzinski K, Pieniazek A, Gwozdzinski L. Reactive oxygen species and their involvement in red blood cell damage in chronic kidney disease. Oxid Med Cell Longev 2021; 2021:6639199.
[25] Hanna RM, Streja E, Kalantar-Zadeh K. Burden of anemia in chronic kidney disease: beyond erythropoietin. Adv Ther 2021; 38:52–75.
[26] Wu HHL, Chinnadurai R. Erythropoietin-stimulating agent hyporesponsiveness in patients living with chronic kidney disease. Kidney Diseases 2022; 8:103–14.
[27] Jain N, Corken AL, Kumar A, Davis CL, Ware J, Arthur JM. Role of platelets in chronic kidney disease. Journal of the American Society of Nephrology 2021; 32:1551–8.
[28] El Kodmiri Z, Ghazi B, Benaddi EH, Ouamani A, Ahnach M. Evaluating Hematological Changes in Hemodialysis Patients: A Retrospective Study in a Moroccan Hospital. Journal of Nursing, Education Sciences, and Medical Practice 2024;1:21–31.
[29] Alzubaidy SA, Mohammed MM, Malik AS. Evaluation of Erythropoietin Stimulating Agent’s Responsiveness and Associated Factors in Hemodialysis Patients with Anemia. Medical Journal of Babylon 2024; 21:551–5.
[30] Zhang H, Fan L, Liao H, Tu L, Zhang J, Xu D, et al. Correlations of cardiac function with inflammation, oxidative stress and anemia in patients with uremia. Exp Ther Med 2021; 21:250.
[31] Gupta J, Mitra N, Kanetsky PA, Devaney J, Wing MR, Reilly M, et al. Association between albuminuria, kidney function, and inflammatory biomarker profile in CKD in CRIC. Clinical Journal of the American Society of Nephrology 2012; 7:1938–46.
[32] Yilmaz MI, Solak Y, Covic A, Goldsmith D, Kanbay M. Renal anemia of inflammation: the name is self-explanatory. Blood Purif 2011; 32:220–5.
[33] Tsai Y-C, Hung C-C, Kuo M-C, Tsai J-C, Yeh S-M, Hwang S-J, et al. Association of hsCRP, white blood cell count and ferritin with renal outcome in chronic kidney disease patients. PLoS One 2012;7: e52775.
[34] Fan F, Jia J, Li J, Huo Y, Zhang Y. White blood cell count predicts the odds of kidney function decline in a Chinese community-based population. BMC Nephrol 2017; 18:190.
[35] Kadatane SP, Satariano M, Massey M, Mongan K, Raina R. The role of inflammation in CKD. Cells 2023; 12:1581.
[36] Sun Y, Jiang L, Shao X. Predictive value of procalcitonin for diagnosis of infections in patients with chronic kidney disease: a comparison with traditional inflammatory markers C-reactive protein, white blood cell count, and neutrophil percentage. Int Urol Nephrol 2017; 49:2205–16.
[37] Hamza E, Metzinger L, Metzinger-Le Meuth V. Uremic toxins affect erythropoiesis during the course of chronic kidney disease: a review. Cells 2020; 9:2039.
[38] Baaten CC, Sternkopf M, Henning T, Marx N, Jankowski J, Noels H. Platelet function in CKD: a systematic review and meta-analysis. Journal of the American Society of Nephrology 2021;32:1583–98.
[39] Fujita Y, Doi Y, Hamano T, Hatazaki M, Umayahara Y, Isaka Y, et al. Low erythropoietin levels predict faster renal function decline in diabetic patients with anemia: a prospective cohort study. Sci Rep 2019; 9:14871.
[40] Panjeta M, Tahirović I, Sofić E, Ćorić J, Dervišević A. Interpretation of erythropoietin and haemoglobin levels in patients with various stages of chronic kidney disease. J Med Biochem 2017; 36:145.
[41] Smith Jr RE. The clinical and economic burden of anemia. Am J Manag Care 2010;16: S59–S66.
[42] Ratcliffe LEK, Thomas W, Glen J, Padhi S, Pordes BAJ, Wonderling D, et al. Diagnosis and management of iron deficiency in CKD: a summary of the NICE guideline recommendations and their rationale. American Journal of Kidney Diseases 2016; 67:548–58.
[43] Lacount S, Tannock LR. Dyslipidemia in chronic kidney disease. Endotext [Internet] 2025.
[44] Nam KH, Chang TI, Joo YS, Kim J, Lee S, Lee C, et al. Association between serum high-density lipoprotein cholesterol levels and progression of chronic kidney disease: results from the KNOW-CKD. J Am Heart Assoc 2019;8: e011162.
[45] Obermayr RP, Temml C, Knechtelsdorfer M, Gutjahr G, Kletzmayr J, Heiss S, et al. Predictors of new-onset decline in kidney function in a general middle-european population. Nephrology Dialysis Transplantation 2008; 23:1265–73.
[46] Bah MS, Togtoga L, Ndong A, Ndoye PD, Niang K, Ndiaye P. Overweight/Obesity: Prevalence and Epidemiological Profile among High School Students in the District of Bamako. Rwanda Public Health Bulletin 2023; 4:12–21.
Downloads
Published
Issue
Section
Categories
License
Copyright (c) 2026 Al-Zahrawi Journal of Medical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
